Overview

Sandostatine® LP and Hyperinsulinism

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.

Phase:

Phase 2

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborator:

Novartis

Treatments:

Octreotide